ANTICARDIOLIPINIC ANTIBODIES IN NON-HODGKIN LYMPHOMA

Código QR

ANTICARDIOLIPINIC ANTIBODIES IN NON-HODGKIN LYMPHOMA

Objective: Identification of hemostasis changes in patients with non-Hodgkin's lymphoma (NHL) and anticardiolipin antibodies (aCL). Methodology: The study included 83 patients (men-34, women-49) with a mean age of 63.2 years, with NHL, investigated complex, by research of lupus anticoagulant (L...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sanda Buruiana, Minodora Mazur, Maria Robu, Victor Tomacinschii
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/acdceef16bc1462c9fd4cf6fc4d45414
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

CLINICAL CHARACTERISTICS, AND SURVIVAL RATE OF ELDERLY PATIENTS WITH NON-HODGKIN'S LYMPHOMAS WITH PRIMARY INVOLVEMENT OF PERIPHERAL LYMPH NODES
por: Tomacinschii Victor, et al.
Publicado: (2021)

MicroRNA dysregulation in B-cell non-Hodgkin lymphoma
por: Lim EL, et al.
Publicado: (2013)

Yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma
por: McKinney MS, et al.
Publicado: (2014)

MEDICAL TREATMENT IN HODGKIN LYMPHOMA
por: Nilgun Kurucu
Publicado: (2021)

PROGNOSIS FACTORS IN AGGRESSIVE NON-HODGKIN LYMPHOMAS WITH PRIMARY INVOLVEMENT OF THE SPLEEN
por: Larisa Musteata, et al.
Publicado: (2021)

Intrasinusoidal Hodgkin Lymphoma; A Mimic of Anaplastic Large Cell Lymphoma
por: John R. Krause, et al.
Publicado: (2021)

Reduced intensity treatment in early-stage Hodgkin&rsquo;s lymphoma
por: Armitage JO, et al.
Publicado: (2011)

Profile of brentuximab vedotin and its potential in the treatment of relapsed or refractory Hodgkin lymphoma
por: Illidge T, et al.
Publicado: (2012)

mTOR inhibitor in the treatment of Hodgkin&rsquo;s lymphoma: a case report
por: Provencio M., et al.
Publicado: (2011)

The Use of Etoposide, Ara-Cytarabine, and Melphalan (EAM) Conditioning Chemotherapy in Autologous Stem Cell Transplantation (ASCT) for a Patient with Relapsed Hodgkin’s Lymphoma
por: Eko A. Pangarsa, et al.
Publicado: (2021)

Bone marrow necrosis in a patient with advanced Hodgkin's lymphoma after G-CSF and Plerixafor treatment during harvesting for autologous bone marrow transplantation: is it possible?
por: Najmaddin Khoshnaw, et al.
Publicado: (2021)

The absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles is not significantly impacted by the use of myeloid growth factors and predicts clinical outcomes in classical Hodgkin lymphoma regardless of their use
por: Kaufman GP, et al.
Publicado: (2014)

Developments in anaplastic large-cell lymphoma: targeting the anaplastic lymphoma kinase
por: Farina F, et al.
Publicado: (2014)

Advances in the diagnosis and management of lymphoma
por: Matasar MJ, et al.
Publicado: (2012)

THE SMALLEST PRIMARY BONE LYMPHOMA
por: Fatma Burçin KURTİPEK, et al.
Publicado: (2021)

MYC as therapeutic target in leukemia and lymphoma
por: Cortiguera MG, et al.
Publicado: (2015)

Peripheral T cell lymphoma: clinical utility of romidepsin
por: Sawey K, et al.
Publicado: (2012)

Preserving fertility in young patients with lymphoma: an overview
por: Patel B, et al.
Publicado: (2014)

MicroRNAs as B-cell lymphoma biomarkers
por: Manterola L, et al.
Publicado: (2015)

Mogamulizumab for the treatment of adult T-cell leukemia/lymphoma
por: Yoshimitsu M, et al.
Publicado: (2014)

THREE CASES WITH BURKITT LYMPHOMA PRESENTING WITH CHOLESTASIS
por: Fatma Tuba YILDIRIM, et al.
Publicado: (2021)

CASE REPORT: FOLLICULAR LYMPHOMA PRESENTED WITH CHYLOTHORAX
por: Senem MARAL, et al.
Publicado: (2021)

Emerging role of SOX11 in mantle cell lymphoma
por: Kuci V, et al.
Publicado: (2015)

A CASE OF MULTI REGIONAL PRIMARY MUSCLE LYMPHOMA
por: Beyza OLUK, et al.
Publicado: (2021)

A RARE CASE: POSTTRANSPLANT NK/T CELL LYMPHOMA
por: Pınar Tığlıoğlu, et al.
Publicado: (2021)

UPSHOTS IN ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA: ANALYSIS OF T-CELL BRAZIL PROJECT
por: Carlos CHIATTONE, et al.
Publicado: (2021)

Immune targeted therapy for diffuse large B cell lymphoma
por: Yaxin Zheng, et al.
Publicado: (2021)

Emerging targets in human lymphoma: targeting the MYD88 mutation
por: Wang JQ, et al.
Publicado: (2013)

BURKITT LYMPHOMA PRESENTING WITH EYE AND KIDNEY INVOLVEMENT: CASE REPORT
por: Aslı Turgutoğlu Yılmaz, et al.
Publicado: (2021)

TREATMENT OF RELAPSED, REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
por: Ebru Pekgüç, et al.
Publicado: (2021)

Monomorphic epitheliotropic intestinal T-cell lymphoma of the duodenum: an aggressive disease
por: Ganesh Kasinathan
Publicado: (2021)

Critical appraisal of belinostat in the management of T-cell lymphoma – patient considerations
por: Bodiford A, et al.
Publicado: (2015)

CAVITARY PRIMARY PULMONARY LYMPHOPLASMOCYTIC LYMPHOMA COMPLICATING HENOCH–SCHÖNLEIN PURPURA
por: Burak GULTEKIN, et al.
Publicado: (2021)

THE EFFECT OF COMORBIDITY AND BODY MASS INDEX ON SURVIVAL IN PATIENTS WITH MARGINAL ZONE LYMPHOMA
por: Esra TURAN ERKEK, et al.
Publicado: (2021)

Primary dural high grade B cell lymphoma mimicking subdural hematoma
por: Aya Nakaya, et al.
Publicado: (2021)

Trends in the treatment of cutaneous T-cell lymphoma &ndash; critical evaluation and perspectives on vorinostat
por: Zhang CL, et al.
Publicado: (2012)

Optimal management of endemic Burkitt lymphoma: a holistic approach mindful of limited resources
por: Moormann AM, et al.
Publicado: (2014)

Treatment strategies for patients with diffuse large B-cell lymphoma: past, present, and future
por: Flowers CR, et al.
Publicado: (2012)

CASE REPORT OF MARGINAL ZONE LYMPHOMA DETECTED WHILE INVESTIGATING ETIOLOGY FOR HEMOSTASIS DISORDER
por: Mesut Tığlıoğlu, et al.
Publicado: (2021)

Splenic marginal zone lymphoma: a review of the clinical presentation, pathology, molecular biology, and management
por: Teixeira Mendes LS, et al.
Publicado: (2014)